Summary & Overview
HCPCS J0584: Burosumab Injection, 1 mg
HCPCS Level II code J0584 denotes a 1 mg unit of burosumab-twza injection, a targeted monoclonal antibody therapy used in disorders of phosphate metabolism. Nationally, accurate reporting of J0584 matters for proper reimbursement, utilization tracking of high-cost biologics, and clinical care coordination for patients requiring parenteral therapy.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and coding context for J0584, national reimbursement and coverage considerations, common places of service for administration, and benchmarking insights where available. The publication highlights payer coverage patterns, prior authorization and medical necessity themes affecting access to burosumab, and coding best practices for clean claims submission.
This summary provides clinical context for when J0584 is used, outlines what documentation typically supports medical necessity, and summarizes the components of a service line involving an injectable biologic. Data not provided in the input (for example, specific payer policy details, ICD-10 pairings, and related codes) are identified as unavailable. The content is intended for national audiences including coding professionals, revenue cycle staff, and clinical administrators evaluating billing and coverage for burosumab therapy.
Billing Code Overview
HCPCS Level II code J0584 represents injection, burosumab-twza, 1 mg. This code describes a single-unit billing entry for the administration of burosumab, a monoclonal antibody therapy indicated for disorders involving phosphate regulation.
Service Type: Drug administration (injectable biologic)
Typical Site of Service: Outpatient infusion or injection setting, such as hospital outpatient departments, physician offices, or specialized infusion centers where parenteral biologic therapies are given.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, or service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult diagnosed with X-linked hypophosphatemia (XLH) presenting with hypophosphatemia-related bone pain, impaired mobility, and growth issues in children. The prescribing specialist (pediatric endocrinologist, adult endocrinologist, or metabolic bone disease specialist) evaluates serum phosphorus, renal function, and radiographic bone findings before initiating therapy. Burosumab-twza is administered by subcutaneous injection J0584 dosed per mg; the clinic schedules visits every 2–4 weeks based on weight and protocol. Prior to injection, the nurse verifies patient identity, reviews recent labs (serum phosphorus, calcium, alkaline phosphatase), documents informed consent and medication lot/expiration, and obtains baseline vitals. The injection is given in an outpatient infusion clinic or ambulatory procedure area; post-injection observation for allergic reaction and injection-site reaction occurs for 15–30 minutes. Billing uses HCPCS Level II code J0584 with appropriate modifier for laterality or service circumstances. Follow-up includes monitoring of serum phosphorus and dose adjustments, and documentation of clinical response and any adverse events in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified — (not commonly used clinically) |